A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Phase 3
330
about 3.9 years
18–99
35 sites in AR, AZ, CA +18
About this study
Researchers are testing whether tarlatamab added to durvalumab, carboplatin, and etoposide prolongs survival compared to durvalumab, carboplatin, and etoposide alone in people with extensive stage small cell lung cancer. The trial will last for about 1427 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin
- 2.Take Durvalumab
- 3.Take Etoposide
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, durvalumab, etoposide, tarlatamab
infusion, injection, intravenous
Primary: Overall Survival (OS), Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)
Secondary: Disease Control, Duration of Response (DOR), Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs), Number of Participants Who Experience Treatment-related Adverse Events, OS Rate, Objective Response (OR), PFS (Investigator Assessed), PFS Rate
Oncology